Articles On Kazia Therapeutics (ASX:KZA)

Title Source Codes Date
Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison

Edison has increased its valuation to A$375 million or A$2.83 per basic share from A$346 million or A$2.68 per basic share mainly due to rolling forward its Net Present Value (NPV).

Proactive Investors KZA 6 days ago
Kazia Therapeutics to Present at LD Micro Main Event

SYDNEY, Oct. 6, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be he...

FNArena KZA 1 week ago
Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Proactive Investors KZA 1 month ago
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference

SYDNEY, Sept. 11, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annua...

FNArena KZA 1 month ago
Hidden Gems Webinar Recap – CYP, AT1, NSB & KZA

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafe KZA 1 month ago
A high quality pipeline of cancer drugs

ShareCafeA high quality pipeline of cancer drugs James Garner – Managing Director & CEO – Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of on...

ShareCafe KZA 1 month ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead KZA 1 month ago
Kazia Therapeutics directors support oncology-focused drug strategy with on-market purchases

“The second calendar quarter has been a busy and productive period for Kazia, as we bed down three substantial cross-border licensing deals,” says CEO.

Proactive Investors KZA 1 month ago
Kazia Therapeutics eyeing commercialisation revenue after “game-changing” FY21

Kazia says its future success will be measured by commercialisation milestones after the company recorded its maiden revenue in the 2021 financial year.

Proactive Investors KZA 1 month ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead KZA 2 months ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead KZA 2 months ago
Kazia Therapeutics has 'busy and productive' June quarter with important readouts slated for second half

All upfront payments from outbound partnering transactions in the first quarter have been received by Kazia.

Proactive Investors KZA 2 months ago
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day

SYDNEY, July 21, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on re...

FNArena KZA 2 months ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead KZA 2 months ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead KZA 3 months ago
3 ASX healthcare shares with big news coming

The fortunes of ASX healthcare shares can often swing on one momentous milestone. Examples of such a make-or-break event could be a breakthrough invention, successful product trial, or regulatory approval (or rejection). Such incidents can...

Motley Fool KZA 3 months ago
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs

SYDNEY, June 30, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801...

FNArena KZA 3 months ago
Kazia Therapeutics makes strong progress with clinical programs for paxalisib and EVT801

The GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm in the US across several prestigious centres.

Proactive Investors KZA 3 months ago
The Information Technology stocks that created buzz today!

Summary Afterpay jumps on plans to expand reach with U.S. merchants Althea enters South African cannabis market worth US$667 million Bluechiip shares close strong on a settlement agreement with Labcon North America The S&P/ASX...

Kalkine Media KZA 3 months ago
ASX ends lower for 2nd day in a row; tech, iron ore stocks fail to lift market sentiment

Summary The ASX 200 closed lower for the second day in a row, falling 0.32% to 7,275.30. The ASX health care and energy stocks were among top losers, while tech and consumer staples emerged as top gainers. Australian retailer Woolwort...

Kalkine Media KZA 3 months ago
Kazia Therapeutics lands key manufacturing patents for paxalisib in US and India

A Kazia-licensed oncology drug has secured manufacturing patents in two key countries, providing an additional layer of protection for the treatment candidate over the next 15 years.

Proactive Investors KZA 3 months ago
Kazia Therapeutics secures new patents for manufacturing process

Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the grant of patents by the respective agencies of the US and India for the manufacturing process for paxalisib.

BiotechDispatch KZA 3 months ago
As neuroscience blurs the line between tech and biology, these ASX brain health stocks are on the frontline

Recent advances in our still-shallow understanding of the human brain have led to a renewed interest in companies that focus on neuroscience. The most famous neuroscience startup, Elon Musk’s Neuralink, is probably the first company that co...

Stockhead KZA 4 months ago
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

SYDNEY, June 15, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medica...

FNArena KZA 4 months ago
Here’s why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost today

Shares in Kazia Therapeutics Ltd (ASX: KZA) lifted today after news its investigational drug Paxalisib will be part of another study for the treatment of brain cancer. At market close, the Kazia share price is $1.40 – 6.87% higher than its...

Motley Fool KZA 4 months ago
Kazia Therapeutics to collaborate with Cornell University for new paxalisib phase II clinical trial

A new study will evaluate the efficacy of Kazia’s paxalisib candidate in patients with newly diagnosed or recurrent glioblastoma when combined with a ketogenic diet and metformin.

Proactive Investors KZA 4 months ago
Alzheimer’s Decision Sends Positive Message to Aussie Biotechs

ShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Administration’s landmark but controversial approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude t...

ShareCafe KZA 4 months ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead KZA 4 months ago
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

SYDNEY, June 7, 2021 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in primar...

FNArena KZA 4 months ago
Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today

The Kazia Therapeutics Ltd (ASX: KZA) share price is edging lower, down 2% in morning trade. Below we take a look at the oncology-focused drug development company’s latest clinical trial update. What update did Kazia provide? Kazia Therape...

Motley Fool KZA 4 months ago
Kazia Therapeutics study of paxalisib in primary CNS Lymphoma at Dana-Farber enrols first patient

The DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL and is expected to recruit up to 25 patients and up to two years to complete.

Proactive Investors KZA 4 months ago
Kazia Therapeutics directors demonstrate confidence in bio-tech strategy with on-market purchases

During the March quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.

Proactive Investors KZA 4 months ago
Invion led a group of ASX cancer stocks up after promising news

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Stockhead KZA 4 months ago
Kazia Therapeutics directors demonstrate confidence in company with on-market purchases

During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.

Proactive Investors KZA 5 months ago
Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business"

During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March. 

Proactive Investors KZA 5 months ago
Kazia Therapeutics bolsters pipeline with new first-in-class oncology drug candidate

Proactive Investors KZA 5 months ago
Kazia Therapeutics’ EVT801 deal secures price target of A$2.60 from Corporate Connect and BUY rating from HC Wainwright

The company gained exclusive global rights to the drug for €1 million (A$1.6 million) upfront, €308 million (A$480 million) in milestones and a tiered single-digit royalty on sales.

Proactive Investors KZA 5 months ago
The Week that Was – April 19-23, 2021

ShareCafeThe Week that Was – April 19-23, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so,...

ShareCafe KZA 5 months ago
Kazia licenses global rights to potential first-in-class oncology drug

Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.

BiotechDispatch KZA 5 months ago
Kazia Therapeutics completes third licensing deal in seven weeks

Kazia Therapeutics (ASX:KZA)‘s chief executive says he could do with catching up on sleep after a “whirlwind” seven weeks in which the $185 million cancer-focused Sydney biotech completed three different cross-border licensing deals. Kazia...

Stockhead KZA 5 months ago
Kazia Therapeutics valuation lifts off the back of in-licensing of EVT901 drug: Edison Group

Much of Kazia’s operational capacity has opened up with the inclusion of paxalisib in the GBM AGILE study, and the company believes that it can dedicate significant resources to the EVT801 program.

Proactive Investors KZA 6 months ago
Kazia Therapeutics licenses global rights to novel, first-in class, clinic-ready oncology drug candidate EVT801

Kazia expects to explore potential uses of EVT801 during the clinical program, including renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer) and soft tissue sarcoma.

Proactive Investors KZA 6 months ago
Kazia Licenses New Oncology Drug Candidate

ShareCafeKazia Licenses New Oncology Drug Candidate Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology focused drug development company has announced that it has entered into a worldwide exclusive licensing agreement and a mas...

ShareCafe KZA 6 months ago
Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

SYDNEY, April 19, 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master...

FNArena KZA 6 months ago
Last Orders: ASX edges slightly higher but still short of all time high

The ASX finished the day higher but the all time high reached prior to COVID-19 still eludes it. The ASX 200 closed at 7,066 points – 0.03 per cent higher than Friday – although the ASX Emerging Companies Index fell by 0.64 per cent to 2,10...

Stockhead KZA 6 months ago
Last Orders: Small caps finish week up 1.4%, outperforming broader market

Small caps have gained again – rising for the fourth day in a row and the 10th time out of 11 sessions. The Small Ordinaries index of the 101st to 300th biggest Australian companies on Friday advanced 17.7 points, or 0.53 per cent to close...

Stockhead KZA 6 months ago
Kazia Therapeutics halted with potential in-licensing transaction announcement pending

Corporate Connect has increased the company’s share price target from A$2.25 to A$2.60 a share on the back of two recent licensing deals.

Proactive Investors KZA 6 months ago
Kazia Therapeutics licensing deals result in A rating and $2.60 price target from Corporate Connect

Kazia Therapeutics has executed two licensing deals in the space of a month, proving the company is capable of identifying highly attractive partners and negotiating equally attractive deals.

Proactive Investors KZA 6 months ago
Uranium explorer 92 Energy eyes ASX listing for mid-April

Uranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or next week after bioenergy company Delorean joined the bourse yesterday. There are four IPOs timed for this week, including Delorean (ASX: DE...

Stockhead KZA 6 months ago
Last Orders: Sixth straight day of gains for small caps

Small caps have gained for a sixth straight day, even as their larger peers declined. The Small Ordinaries index of Australia’s 101st to 300th biggest companies finished the week up 6.7 points, or 0.2 per cent, to a fresh 13-year high of 3,...

Stockhead KZA 6 months ago